BioRestorative rises on preliminary data for bone disease cell therapy

Biorestorative Therapies

13/11/2024 13:00

** Shares of drug developer BioRestorative Therapies
 BRTX.O  rise ~7% to $1.75 premarket   
    ** Co reports preliminary data from ongoing mid-stage study
testing BRTX-100, its lead cell therapy candidate to treat
chronic lumbar disc disease
    ** Lumbar disc disease, also known as degenerative disc
disease, occurs when spinal discs in lower back area begins to
wear away   
    ** No serious side-effects were reported in 10 safety run-in
subjects, BRTX says
    ** Co says blinded data from 10 trial participants showed
BRTX-100 helped improve pain and function    
    ** Up to last close, stock down ~6% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))